Steroid eye drops + Vasoconstrictor eye drops + Ophthalmic steroid ointment + Depatuxizumab mafodotin + Temozolomide
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme
Trial Timeline
Jul 30, 2018 → Mar 3, 2020
NCT ID
NCT03419403About Steroid eye drops + Vasoconstrictor eye drops + Ophthalmic steroid ointment + Depatuxizumab mafodotin + Temozolomide
Steroid eye drops + Vasoconstrictor eye drops + Ophthalmic steroid ointment + Depatuxizumab mafodotin + Temozolomide is a phase 3 stage product being developed by AbbVie for Glioblastoma Multiforme. The current trial status is terminated. This product is registered under clinical trial identifier NCT03419403. Target conditions include Glioblastoma Multiforme.
What happened to similar drugs?
1 of 17 similar drugs in Glioblastoma Multiforme were approved
Approved (1) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03419403 | Phase 3 | Terminated |
Competing Products
20 competing products in Glioblastoma Multiforme